{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:03:57Z","timestamp":1745298237065,"version":"3.37.3"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T00:00:00Z","timestamp":1724630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Fundamental Research Funds"},{"name":"Central Universities of China","award":["226-2022-00035"],"award-info":[{"award-number":["226-2022-00035"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mucopolysaccharidosis (MPS) IVA is a lysosomal storage disorder caused by mutations in the gene encoding the galactosamine (N-acetyl)-6-sulfatase (GALNS) enzyme. Children with MPS IVA usually develop pectus carinatum, genu valgum and multiple skeletal abnormalities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>To establish a patient-derived induced pluripotent stem cell (iPSC) disease model to investigate the effects of two GALNS missense mutations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The medical history and clinical manifestations of a patient with MPS IVA were first inspected. The effects of the identified GALNS mutations were predicted through bioinformatic analysis. iPSCs were then generated by using Sendai virus to introduce Yamanaka reprogramming factors to urinary cells isolated from the patient. The pluripotency, karyotypic integrity, genetic mutations and differentiation ability of the iPSCs were tested. The effects of the GALNS mutations were further experimentally characterized using patient-derived cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The patient exhibited a typical MPS IVA phenotype. Enzyme replacement therapy could not correct her skeletal abnormalities. GALNS c.485C&amp;gt;A (p.S162Y) and c.494G&amp;gt;T (p.C165F) mutations, inherited from her father and mother, respectively, were identified in the patient. These two mutations were predicted to disturb the hydrophobic core of the GALNS catalytic domain. Patient-derived iPSCs were successfully generated, and further characterization indicated that the two missense mutations significantly diminished GALNS activity without affecting its amount at both the RNA and protein levels.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We established a novel clinically relevant MPS IVA disease model that will be useful not only for investigating the pathogenic mechanisms of MPS IVA variants but also for drug screening and preclinical evaluation of novel therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/qjmed\/hcae164","type":"journal-article","created":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T14:24:56Z","timestamp":1724682296000},"page":"17-23","source":"Crossref","is-referenced-by-count":1,"title":["Diminished GALNS activity in induced pluripotent stem cells of mucopolysaccharidosis IVA caused by compound p.S162Y and p.C165F mutation"],"prefix":"10.1093","volume":"118","author":[{"given":"X","family":"Jiang","sequence":"first","affiliation":[{"name":"Birth Defects and Rare Diseases Research Center, Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Chen","sequence":"additional","affiliation":[{"name":"Birth Defects and Rare Diseases Research Center, Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Jiang","sequence":"additional","affiliation":[{"name":"Birth Defects and Rare Diseases Research Center, Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Chen","sequence":"additional","affiliation":[{"name":"Birth Defects and Rare Diseases Research Center, Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Chen","sequence":"additional","affiliation":[{"name":"Birth Defects and Rare Diseases Research Center, Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Bai","sequence":"additional","affiliation":[{"name":"Birth Defects and Rare Diseases Research Center, Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Yu","sequence":"additional","affiliation":[{"name":"Birth Defects and Rare Diseases Research Center, Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8988-7362","authenticated-orcid":false,"given":"W","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health , Hangzhou 310052,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,8,26]]},"reference":[{"issue":"Suppl. 5","key":"2025021719054993100_hcae164-B1","doi-asserted-by":"crossref","first-page":"v4","DOI":"10.1093\/rheumatology\/ker394","article-title":"Overview of the mucopolysaccharidoses","volume":"50","author":"Muenzer","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2025021719054993100_hcae164-B2","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3390\/ijms21041517","article-title":"Mucopolysaccharidosis IVA: diagnosis, treatment, and management","volume":"21","author":"Sawamoto","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025021719054993100_hcae164-B3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jmb.2012.08.020","article-title":"The structure of human GALNS reveals the molecular basis for mucopolysaccharidosis IV A","volume":"423","author":"Rivera-Col\u00f3n","year":"2012","journal-title":"J Mol Biol"},{"volume-title":"GeneReviews\u00ae","year":"2013","author":"Regier","key":"2025021719054993100_hcae164-B4"},{"key":"2025021719054993100_hcae164-B5","doi-asserted-by":"crossref","first-page":"16148","DOI":"10.3390\/ijms242216148","article-title":"Mucopolysaccharidosis IVA: current disease models and drawbacks","volume":"24","author":"Leal","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025021719054993100_hcae164-B6","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1093\/hmg\/ddg366","article-title":"Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (GALNS-\/-) produced by targeted disruption of the gene defective in Morquio A disease","volume":"12","author":"Tomatsu","year":"2003","journal-title":"Hum Mol Genet"},{"key":"2025021719054993100_hcae164-B7","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1093\/hmg\/ddi364","article-title":"Development of MPS IVA mouse (Galnstm(hC79S.mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase","volume":"14","author":"Tomatsu","year":"2005","journal-title":"Hum Mol Genet"},{"key":"2025021719054993100_hcae164-B8","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ymgme.2007.02.009","article-title":"Murine model (Galns(tm(C76S)slu)) of MPS IVA with missense mutation at the active site cysteine conserved among sulfatase proteins","volume":"91","author":"Tomatsu","year":"2007","journal-title":"Mol Genet Metab"},{"key":"2025021719054993100_hcae164-B9","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1242\/dmm.029009","article-title":"Induced pluripotent stem cell models of lysosomal storage disorders","volume":"10","author":"Borger","year":"2017","journal-title":"Dis Model Mech"},{"key":"2025021719054993100_hcae164-B10","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/hmg\/ddx442","article-title":"Gaucher disease iPSC-derived osteoblasts have developmental and lysosomal defects that impair bone matrix deposition","volume":"27","author":"Panicker","year":"2018","journal-title":"Hum Mol Genet"},{"key":"2025021719054993100_hcae164-B11","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.3390\/ijms21176124","article-title":"Versatility of induced pluripotent stem cells (iPSCs) for improving the knowledge on musculoskeletal diseases","volume":"21","author":"Sanjurjo-Rodr\u00edguez","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025021719054993100_hcae164-B12","doi-asserted-by":"crossref","first-page":"116760","DOI":"10.1016\/j.bone.2023.116760","article-title":"Induced pluripotent stem cell technology in bone biology","volume":"172","author":"Kidwai","year":"2023","journal-title":"Bone"},{"key":"2025021719054993100_hcae164-B13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1007\/s13577-024-01031-8","article-title":"Establishment and characterization of ZJUCHi003: an induced pluripotent stem cell line from a patient with Temple-Baraitser\/Zimmermann-Laband syndrome carrying KCNH1 c.1070G&gt;A (p.R357Q) variant","volume":"37","author":"Chen","year":"2024","journal-title":"Hum Cell"},{"key":"2025021719054993100_hcae164-B14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0009-8981(90)90339-T","article-title":"A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A)","volume":"187","author":"van Diggelen","year":"1990","journal-title":"Clin Chim Acta"},{"key":"2025021719054993100_hcae164-B15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/geno.1994.1132","article-title":"Mucopolysaccharidosis IV A: molecular cloning of the human N-acetylgalactosamine-6-sulfatase gene (GALNS) and analysis of the 5'-flanking region","volume":"20","author":"Nakashima","year":"1994","journal-title":"Genomics"},{"key":"2025021719054993100_hcae164-B16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/jimd.12491","article-title":"Investigation of GALNS variants and genotype-phenotype correlations in a large cohort of patients with mucopolysaccharidosis type IVA","volume":"45","author":"Yi","year":"2022","journal-title":"J Inherit Metab Dis"},{"key":"2025021719054993100_hcae164-B17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2147\/TACG.S141881","article-title":"Determination of genotypic and clinical characteristics of Colombian patients with mucopolysaccharidosis IVA","volume":"11","author":"Tapiero-Rodriguez","year":"2018","journal-title":"Appl Clin Genet"},{"key":"2025021719054993100_hcae164-B18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.gene.2012.12.100","article-title":"Identification of a novel missense mutation in Brazilian patient with a severe form of mucopolysaccharidosis type IVA","volume":"517","author":"Kubaski","year":"2013","journal-title":"Gene"},{"key":"2025021719054993100_hcae164-B19","doi-asserted-by":"crossref","first-page":"101408","DOI":"10.1016\/j.scr.2019.101408","article-title":"Generation of an induced pluripotent stem cell line (TRNDi005-A) from a mucopolysaccharidosis type IVA (MPS IVA) patient carrying compound heterozygous p.R61W and p.WT405del mutations in the GALNS gene","volume":"36","author":"Li","year":"2019","journal-title":"Stem Cell Res"},{"key":"2025021719054993100_hcae164-B20","doi-asserted-by":"crossref","first-page":"15045","DOI":"10.1038\/s41598-022-19407-x","article-title":"Delivery and assessment of a CRISPR\/nCas9-based genome editing system on in vitro models of mucopolysaccharidoses IVA assisted by magnetite-based nanoparticles","volume":"12","author":"Leal","year":"2022","journal-title":"Sci Rep"},{"key":"2025021719054993100_hcae164-B21","doi-asserted-by":"crossref","first-page":"e2211510120","DOI":"10.1073\/pnas.2211510120","article-title":"Modeling human skeletal development using human pluripotent stem cells","volume":"120","author":"Lamand\u00e9","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"2025021719054993100_hcae164-B22","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.clinthera.2016.11.017","article-title":"Long-term immunogenicity of elosulfase alfa in the treatment of Morquio A syndrome: results from MOR-005, a phase III extension study","volume":"39","author":"Long","year":"2017","journal-title":"Clin Ther"},{"key":"2025021719054993100_hcae164-B23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1517\/21678707.2015.1086640","article-title":"Enzyme replacement therapy for treating mucopolysaccharidosis type IVA (Morquio A syndrome): effect and limitations","volume":"3","author":"Tomatsu","year":"2015","journal-title":"Expert Opin Orphan Drugs"},{"key":"2025021719054993100_hcae164-B24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s10038-019-0604-6","article-title":"Effect of enzyme replacement therapy on the growth of patients with Morquio A","volume":"64","author":"Doherty","year":"2019","journal-title":"J Hum Genet"},{"key":"2025021719054993100_hcae164-B25","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.3390\/ijms20174139","article-title":"Development of substrate degradation enzyme therapy for mucopolysaccharidosis IVA murine model","volume":"20","author":"Sawamoto","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025021719054993100_hcae164-B26","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1021\/acsmedchemlett.0c00042","article-title":"Bromocriptine as a novel pharmacological chaperone for mucopolysaccharidosis IV A","volume":"11","author":"Olarte-Avellaneda","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"2025021719054993100_hcae164-B27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.omtm.2020.05.015","article-title":"Liver-Targeted AAV8 gene therapy ameliorates skeletal and cardiovascular pathology in a mucopolysaccharidosis IVA murine model","volume":"18","author":"Sawamoto","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2025021719054993100_hcae164-B28","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1038\/s41467-021-25697-y","article-title":"Treatment of skeletal and non-skeletal alterations of mucopolysaccharidosis type IVA by AAV-mediated gene therapy","volume":"12","author":"Bertolin","year":"2021","journal-title":"Nat Commun"}],"container-title":["QJM: An International Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/qjmed\/advance-article-pdf\/doi\/10.1093\/qjmed\/hcae164\/59188962\/hcae164.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/118\/1\/17\/59188962\/hcae164.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/qjmed\/article-pdf\/118\/1\/17\/59188962\/hcae164.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:06:13Z","timestamp":1739819173000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/qjmed\/article\/118\/1\/17\/7741650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,26]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,26]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/qjmed\/hcae164","relation":{},"ISSN":["1460-2725","1460-2393"],"issn-type":[{"type":"print","value":"1460-2725"},{"type":"electronic","value":"1460-2393"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,26]]}}}